The estimated Net Worth of Michael Lefenfeld is at least $389 millier dollars as of 24 May 2021. Michael Lefenfeld owns over 4,650 units of Immunome stock worth over $388,569 and over the last 4 years Michael sold IMNM stock worth over $0.
Sign up
Michael Lefenfeld IMNM stock SEC Form 4 insiders trading
Michael has made over 1 trades of the Immunome stock since 2021, according to the Form 4 filled with the SEC. Most recently Michael bought 4,650 units of IMNM stock worth $86,165 on 24 May 2021.
The largest trade Michael's ever made was buying 4,650 units of Immunome stock on 24 May 2021 worth over $86,165. On average, Michael trades about 664 units every 0 days since 2020. As of 24 May 2021 Michael still owns at least 26,872 units of Immunome stock.
You can see the complete history of Michael Lefenfeld stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Michael Lefenfeld's mailing address?
Michael's mailing address filed with the SEC is C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON, PA, 19341.
Insiders trading at Immunome
Over the last 4 years, insiders at Immunome have traded over $0 worth of Immunome stock and bought 480,004 units worth $5,722,735 . The most active insiders traders include Clay B Siegall, Jean Jacques Bienaime et Michael Rapp. On average, Immunome executives and independent directors trade stock every 84 days with the average trade being worth of $518,362. The most recent stock trade was executed by Jean Jacques Bienaime on 15 August 2024, trading 7,000 units of IMNM stock currently worth $97,580.
What does Immunome do?
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
What does Immunome's logo look like?
Complete history of Michael Lefenfeld stock trades at Immunome
Immunome executives and stock owners
Immunome executives and other stock owners filed with the SEC include:
-
Dr. Purnanand Duddu Sarma,
Pres, CEO & Director -
Sandra G. Stoneman Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Michael J. Morin Ph.D.,
Chief Scientist -
Dr. Scott K. Dessain M.D., Ph.D.,
Co-founder & Chairman of the Scientific Advisory Board -
Dr. Dennis H. Giesing,
Chief Devel. Officer -
Matthew K. Robinson Ph.D.,
Sr. VP of R&D -
Corleen M. Roche,
Chief Financial Officer -
Michael Widlitz,
Director -
Michael Lefenfeld,
Director -
Dennis H Giesing,
Chief Development Officer -
Jean Jacques Bienaime,
-
Max Rosett,
EVP, Operations & CFO -
James P Boylan,
-
Philip Tsai,
Chief Technology Officer -
Franklyn G Prendergast,
Director -
Sandra M Swain,
-
I Wistar Iii Morris,
10% owner -
Richard F Fitzgerald,
Chief Financial Officer -
John L Lamattina,
Director -
Michael Rapp,
Director -
Corleen M. Roche,
Chief Financial Officer -
Philip Wagenheim,
-
Richard A Baron,
Director -
Matthew K Robinson,
Chief Technology Officer -
Purnanand D Sarma,
President and CEO -
Clay B Siegall,
President and CEO -
Isaac Barchas,
-
Phil Noland Roberts,
Chief Technology Officer -
Carol Schafer,
-
Kinney Horn,
CHIEF BUSINESS OFFICER -
Jack Higgins,
Chief Scientific Officer -
Robert Lechleider,
Chief Medical Officer -
Bruce Turner,
Chief Strategy Officer